Paclitaxel, bropirimine and linomide: Effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 20, Issue 2, 1998, Pages 111-114

  Shaw, Michael ^b   Ratanawong, Saki ^b   Chou, Pauline ^b   Ray, Vera ^b   Mirochnik, Yelena ^b   Slobodskoy, Leonid ^b   Rubenstein, Marvin ^b   Guinan, Patrick ^a  

^a Hektoen Institute for Medical Research   (United States)

^b NONE

Author keywords

Bropirimine; Chemotherapy; Linomide; Paclitaxel; Prostate cancer

Indexed keywords

BROPIRIMINE; PACLITAXEL; ROQUINIMEX;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; DRUG MECHANISM; GROWTH INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PROSTATE CANCER; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CYTOSINE; HYDROXYQUINOLINES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MODELS, BIOLOGICAL; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, INBRED F344;

EID: 0031953955     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1998.20.2.481838     Document Type: Article

References (19)

1. Parker, S., Tong, T., Golden, S., Wingo, P. Cancer statistics. Ca Cancer J Clin 1997, 47: 5-27.
2. Eisenberger, M.A., Abrams, J.S. Chemotherapy for prostatic carcinoma. Semin Urol 1988, 6: 303-10.
3. Smith, D.C., Bahnson, R.R., Trump, D.L. Management of hormone-refractory disease. In: Comprehensive Textbook of Genitourinary Oncology. Vogelzang, N.J., Scardino, P.T., Shipley, W.U., Coffey, D.S. (Eds.). Williams and Williams: Baltimore 1996, 885-91.
4. Moore, M.R., Troner, M.B., DeSimone, P., Birch, R., Irwin, L. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 1986, 70: 541-3.
5. Benson, R., Hartley-Asp, B. Mechanisms of action and clinical uses of estramustine. Cancer Invest 1990, 8: 375-80.
6. Scher, H.I. Suramin: Here to stay? J Natl Cancer Inst 1993, 85: 594-7.
7. Isaacs, J.T., Isaacs, W.B., Wouter, F.J., Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. The Prostate 1986, 9: 261-81.
8. Schiff, P., Horowitz, S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980, 77: 1561-5.
9. Rao, S., Horowitz, S.B., Ringel, I. Direct photoaffinity labeling of tabulin with taxol. J Natl Cancer Inst 1992, 84: 785-8.
10. Smith, D.C., Esper, P.S., Todd III, R.F.K, Pienta, K.J. Paclitaxel, estramustine, and etoposide in patients with hormone refractory prostate cancer (HRPC): A phase II trial. Proceedings ASCO 1997, 16: 310a.
11. Peereboom, D.M., Klein, E., Olencki, T. et al. Phase I trial of paclitaxel and estramustine in hormone refractory prostate cancer. Proceedings ASCO 1996, 15: 263a.
12. Bubendorf, L., Sauter, G., Moch, H. et al. Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 1996, 148: 1557-65.
13. Apikram, I., Robinson, M.C., Walter, N.M. et al. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996, 74: 1258-62.
14. Li, L.H., Wallace, T.L., Wierenga, W., Skulnick, H.I., DeKoning, T.F. Antitumor activity of pyrimidinones, a class of small-molecule biological response modifiers. J Biol Resp Modif 1987, 6: 44-55.
15. Lievano, G., DiDomenico, D., Brown, J. et al. Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-β in a rat orthotopic prostate adenocarcinoma. Meth Find Exp Clin Pharmacol 1997, 19(4): 261-7.
16. Sarosdy Personal Communication.
17. Kita, M., Kunihara, M. Anti-proliferative action of bropirimine (U-54461 S) in human bladder cell lines in vitro. Upjohn Technical Report 1992, 1470-92-050, December 11.
18. Joseph, I.B.J.K., Vukanovic, J., Isaacs, J.T. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res 1996, 56: 3404-8.
19. Vukanovic, J., Passaniti, A., Hirata, T., Traystman, R.J., Hartley-Asp, B., Isaacs, J.T. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 1993, 53: 1833-7.